Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›ALPS›SBIO

SBIO

ALPS Medical Breakthroughs ETF

Passive ETF Equity Theme: Tomorrow's Treatments

The SBIO Exchange Traded Fund (ETF) is provided by ALPS. It is built to track an index: S-Network Medical Breakthroughs Index. The SBIO ETF provides physical exposure, so by buying it you actually own parts of all the 104 underlying holdings. This share class generates a stream of income by distributing dividends.

$66.84

+$0.55 (+0.83%) today

5:16 PM 08/06/26 Open

1D price range

$66.84$67.61

52W price range

$32.79$68.83

YTD Perf.

+29.75%

YTD Flows

Annualized volatility

Fund AuM

€182M

Share class AuM

€182M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US00162Q5936

TER

0.5%

Inception date

12/30/2014

Issuer

ALPS

Benchmark

S-Network Medical Breakthroughs Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
LFSC F/m Emerald Life Sciences Innovation ETF	+5.62%
BBC Virtus LifeSci Biotech Clinical Trials ETF	+5.71%
PSCH Invesco S&P SmallCap Health Care ETF	+1.66%
XBI State Street SPDR S&P Biotech ETF	+3.42%
CURE Global X S&P Biotech ETF	+1.47%
AAKG ARK Genomic Revolution UCITS ETF	+10.43%
ARKG ARK Genomic Revolution ETF	+10.12%
PTH Invesco DWA Healthcare Momentum ETF	+5.38%
XPH State Street SPDR S&P Pharmaceuticals ETF	+1.70%
IBRN iShares Neuroscience and Healthcare ETF	+2.97%
XHE State Street SPDR S&P Health Care Equipment ETF	+2.32%
FMED Fidelity Disruptive Medicine ETF	+1.27%
GNOG Global X Genomics & Biotechnology UCITS ETF	+4.43%
GNOM Global X Genomics & Biotechnology ETF	+4.44%
HELX Franklin Genomic Advancements ETF	+3.09%

API

PerformanceDec 31, 2025 - Aug 5, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

99.06%

Unavailable

0.93%

Latest SBIO news

No content available for this fund

FAQ about SBIO

SBIO is a Passive ETF. This ETF provides exposure to Mid and Small-Cap US Equities.

SBIO tracks the S-Network Medical Breakthroughs Index NTR - USD, through a full replication replication method.

SBIO carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.

SBIO was introduced to the market on December 30, 2014. It trades on United States

ALPS Medical Breakthroughs ETF, SBIO, is provided by ALPS. Learn more about ALPS here.

SBIO oversees €182M in assets as of August 5, 2026.

SBIO follows a distributing dividend policy, meaning it pays out income to investors.

As of June 30, 2026, SBIO has significant geographic allocations in USA, Canada and Netherlands.

As of June 30, 2026, SBIO focuses largely on Healthcare.

As of June 30, 2026, SBIO holds 104 positions in its portfolio, with 40.08% of assets concentrated in its top 15 holdings.

As of June 30, 2026, SBIO top three holdings include Apogee Therapeutics, Inc., CG Oncology, Inc. and Xenon Pharmaceuticals, Inc..

The base currency of SBIO is USD.

Top 10 holdings

Data as of 06/30/26

Apogee Therapeutics, Inc.

4.36%

CG Oncology, Inc.

3.33%

Xenon Pharmaceuticals, Inc.

3.09%

Oruka Therapeutics, Inc.

3.05%

Dianthus Therapeutics, Inc.

2.83%

Travere Therapeutics, Inc.

2.80%

Definium Therapeutics, Inc.

2.73%

Veradermics, Inc.

2.72%

Edgewise Therapeutics, Inc.

2.32%

ACADIA Pharmaceuticals, Inc.

2.30%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

ALPS Medical Breakthroughs ETF

FAQ about SBIO

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US